Brief: Erasca Announces Publication Of Promising Clinical Data Supporting The Therapeutic Potential Of Naporafenib In Combination With Trametinib In Nras-Mutant Melanoma
25/04/2023 13:52
Erasca Inc ERAS.O :
* ERASCA ANNOUNCES PUBLICATION OF PROMISING CLINICAL DATA
SUPPORTING THE THERAPEUTIC POTENTIAL OF NAPORAFENIB IN
COMBINATION WITH TRAMETINIB IN NRAS-MUTANT MELANOMA
* ERASCA INC - DOSING OF FIRST PATIENT IN ERASCA'S PIVOTAL
PHASE 3
TRIAL IN NRASM MELANOMA (SEACRAFT-2) IS EXPECTED IN H1 2024
Source text for Eikon: ID:nGNXbFjqkC
Further company coverage: ERAS.O